What the Medicare GLP-1 Bridge means for your front desk

Great news for Medicare beneficiaries: the Medicare GLP-1 Bridge demonstration—running through 2027—offers select weight loss drugs (Wegovy, Foundayo, Zepbound KwikPen) for $50/month outside Part D. However, with strict clinical rules, answering "do I qualify?" is rarely a simple yes or no.

Hello Patient’s AI agents handle high-volume inquiries about programs like the GLP-1 Bridge by answering calls, texts, and web chats concurrently across all lines. They deliver practice-approved program details, schedule patient evaluations, and process refill requests automatically—transferring all clinical decisions directly to your team with full conversation transcripts for reference.

How to determine which patients qualify for the GLP-1 Bridge

Fewer people qualify than media coverage suggests, and the criteria depend on specific moving parts.

Eligibility relies on the patient's BMI when they started GLP-1 therapy—including those who began treatment prior to July 2026—rather than their BMI on the day of the inquiry. A BMI of 35 or higher qualifies automatically for patients aged 18 and older. For a BMI between 30 and 34.9, qualification requires a co-occurring diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension (blood pressure above 140/90 on two medications), or stage 3a or higher chronic kidney disease. For a BMI between 27 and 29.9, the patient must be over the age of 18, and have pre-diabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease.

Another hurdle is clinical exclusions. Patients with Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH receive GLP-1s through standard Part D plans even if they meet the above criteria. 

Coverage also depends on the patient's specific plan, requiring enrollment in a standalone Part D or eligible Medicare Advantage plan with drug coverage. Prescribers must also formally attest to ongoing lifestyle modifications.

According to KFF data, while nearly 13 million Medicare beneficiaries meet the initial BMI threshold, fewer than 4 million satisfy all clinical, diagnostic, and plan criteria. Hearing the $50 headline does not guarantee qualification meaning every inquiry requires a thorough, individual conversation.

Questions patients may have about the program

The Medicare GLP-1 Bridge triggers a wave of patient questions across phone, text, and web chat. Beyond asking if they qualify, existing GLP-1 patients frequently ask if they can get their medication for $50 now. There is never a simple yes or no answer.

Appointment requests naturally follow. While CMS (Centers for Medicare & Medicaid Services) does not mandate a new office visit—allowing prescribers to attest directly from existing chart data before the pharmacy claim triggers prior authorization—many practices prefer to require an evaluation. Whether to assess baseline eligibility or update medical records for attestation, that decision rests entirely with the practice, turning every interested patient into a potential booking request.

The 72-hour review window creates another influx of inquiries from patients checking on approval status, as CMS mails decisions to patients while notifying prescribers directly. Meanwhile, refill requests follow 28- or 30-day dispensing cycles. Because approvals remain valid through December 31, 2027—without requiring new prior authorizations unless the drug changes—refills represent a routine touchpoint rather than a recurring hurdle.

Writing in STAT, one primary care physician noted that the administrative workload of GLP-1 prescribing often rivals the clinical work, landing primarily on primary care. While just one physician's perspective, it mirrors reality: these touchpoints are largely administrative, highly predictable, and require an efficient system to respond.

Who is responsible for answering these questions?

Nearly 4 million people meet the full eligibility criteria—not counting the millions who will ask and hear no. The practices receiving these calls are already stretched. AMN Healthcare's survey put the average wait for a new family-medicine appointment at 23.5 days across 15 major metros.

Patients also have nowhere obvious to turn. A Mayo Clinic Proceedings study counted 9,423 board-certified obesity-medicine physicians across the U.S., practicing in just 1,003 of the country's 3,143 counties. With over two-thirds of counties lacking a local specialist, patients naturally bring their Bridge questions to their primary practice.

This demand was building long before the program launched. Medicare GLP-1 claims roughly quadrupled from 2019 to 2024, jumping from under 5 million to nearly 22 million without a $50 copay in place. The Bridge didn't start this wave—it just gave patients a reason to call, and your practice is the one answering.

Where an AI agent fits in

The agent handles the conversations and bookings, leaving medical decisions to your prescribers.

It answers calls, texts, and web chats simultaneously across all lines, delivering your practice's exact, approved messaging on program details and refills. When you require an evaluation, it asks your intake questions and books appointments directly into your schedule. Hello Patient integrates with the EHR, practice management, and CRM systems healthcare runs on like ModMed, athenahealth, and eClinicalWorks to keep everything in your existing workflow.

The agent never offers medical advice or determines qualification. Whenever clinical judgment is needed, it hands off to your staff alongside a written summary of the conversation.

Pulse MD is a multi-location urgent care provider in New York that cut missed calls down from 26% to zero within 30 days of putting an AI agent on its phones. Hear how it sounds, or request a free demo agent for your practice by booking a call.

What’s next for the program

The Bridge ends December 31, 2027. CMS has delayed the Medicare arm of the follow-on BALANCE model and says potential future implementation remains under evaluation, with no confirmed program in place once it concludes.

As the expiration approaches, coverage-transition questions will spike from patients wanting to know what happens next. Proactive outreach addresses these concerns before a flood of questions start hitting your practice.

A study cited in a federal ASPE brief found that more than half of patients discontinued semaglutide use within a year. Staying on the drug isn't always the goal, and deciding to restart requires clinical judgment. However, practices need a structured way to check in when patients stop, rather than waiting for an annual visit.

This is where the agent's outbound capabilities come in. It runs automated recall and follow-up campaigns via call and text, handling all initial replies. Practices using these workflows book roughly 20% more appointments without adding staff.

How to prepare your practice 

First, decide what your practice's Bridge process actually is: who assesses eligibility, whether you want a visit before prescribing, what the front desk says when specific questions like, ‘how do I qualify?’ come in, and how refill requests route and who approves them. Right now that answer probably varies by location and by whoever picks up.

Second, write the approved answers down, the ones a new hire or AI agent would need on day one. 

The third step is the evaluation. If you are looking at an AI agent for this, ask the vendor three questions: does it book real appointments into your EHR under your rules, what exactly happens when a caller asks a clinical question, and can it run the outbound side too, the recalls and the 2027 outreach? Ask the compliance question as well—confirming HIPAA, SOC 2, and a signed BAA—before anything talks to a patient.

Discover Hello Patient

Find out if Hello Patient fits your clinical practice. Schedule a personalized consultation to review how our platform operates within your current EHR environment, and request a live demo agent to experience how the interaction sounds to your patients

Frequently asked questions

Is the Medicare GLP-1 Bridge part of Medicare Part D?

No. The Bridge is a short-term CMS demonstration that runs outside Part D's normal flow, with a single central processor, Humana, handling it nationwide at a $50 monthly copay. Patients still need drug coverage to use it: the program requires enrollment in a standalone Part D plan or a Medicare Advantage plan with drug coverage, and several plan types are out. That distinction confuses patients, and it is one of the program questions a Hello Patient agent can answer in your practice's approved wording, the same way on every call. The Bridge runs from July 1, 2026 through December 31, 2027 and covers Wegovy, Foundayo, and the Zepbound KwikPen for weight reduction and maintenance.

Do patients with type 2 diabetes qualify for the Medicare GLP-1 Bridge?

No. CMS excludes type 2 diabetes from the Bridge, along with moderate-to-severe obstructive sleep apnea and noncirrhotic MASH. Patients with those conditions get GLP-1 coverage through their regular Part D plan instead, even when they meet the program's BMI criteria. A Hello Patient agent can explain that distinction in your practice's wording and route the patient to the right next step, without ever making the eligibility determination itself. Whether a specific patient qualifies for anything is a clinical call your prescriber makes, never the agent.

Does a patient need an appointment to get a GLP-1 through the Bridge?

Not as a program requirement. CMS does not require a new office visit; the prescriber attests to the patient's BMI at initiation, the qualifying diagnoses, and lifestyle-modification counseling based on what is already in the chart. Many practices will still want a visit first, to assess eligibility, update the record, or gather what the attestation needs, and that is each practice's decision to make. When your practice does want one, a Hello Patient agent can take the appointment request by phone, text, or web chat and book the right visit type directly into your schedule, so the request never sits in a voicemail queue.

How can an AI agent handle "do I qualify for the GLP-1 Bridge?" calls without giving medical advice?

By answering program questions and leaving eligibility to the prescriber. A Hello Patient agent explains what the Bridge is, what the copay is, and what your practice's process looks like, in wording your practice approves. It never tells a patient whether they qualify, because that is a clinical determination the prescriber makes based on BMI at initiation and the qualifying diagnoses. When a caller asks a clinical question, the agent hands the conversation to your staff with a written summary of what was said.

How does the GLP-1 Bridge prior authorization actually work?

It starts at the pharmacy, not with a form from your office. Per CMS's provider FAQ, the prescriber determines eligibility and sends the prescription to the pharmacy first. The pharmacy's claim triggers the prior authorization request, which reaches the prescriber electronically or by fax, typically within 24 to 72 hours. The prescriber attests to BMI at initiation, the qualifying diagnoses, and lifestyle-modification counseling, and the approval or denial goes out within 72 hours of submission. There is no appeals process, but a prescriber can resubmit with corrected information. An approval stays valid through December 31, 2027, so refills need no new prior authorization unless the patient switches drugs. A Hello Patient agent can handle the status questions this window creates.

When does the Medicare GLP-1 Bridge end, and what should practices plan for?

December 31, 2027. CMS has delayed the Medicare arm of the follow-on BALANCE model and says potential future implementation remains under evaluation, so there is no confirmed program waiting on the other side. Staying power is also uneven along the way: a study cited in the federal ASPE brief found 52.5% of semaglutide patients treated for overweight or obesity discontinued within a year. As the date approaches, practices may face coverage-transition questions from patients who got their GLP-1 through the Bridge, and proactive outreach may make sense before those questions arrive on their own. A Hello Patient agent can run that outreach by call and text and handle the replies, alongside answering the inbound questions.

Is Hello Patient HIPAA-compliant?

Yes. Hello Patient is HIPAA-compliant and SOC 2 Type 2 certified, and signs a business associate agreement with every client. Patient conversations about a Medicare drug program touch protected health information, so that floor matters before anything talks to a patient. The agents handle calls, texts, and web chats inside that framework, and anything that needs human judgment goes to your staff with a written summary of the conversation. For more detail on what HIPAA compliance means for an AI agent answering your phones, see our guide to HIPAA-compliant AI receptionists.